Trulieve (TRLV) Q3 2026 Earnings Call Transcript

Trulieve reported Q3 2026 medical revenue of $230.2 million, up 4% year over year and sequentially, with a 64.3% gross margin and adjusted EBITDA of $89.2 million; management said results exceeded guidance. The company ended the quarter with $326.7 million in cash and $289.4 million in debt, repaid $65 million of mortgage notes after quarter-end, and raised full-year capital expenditure guidance to $105 million from $95 million, mainly to expand Georgia cultivation. Q4 revenue is expected to grow by low single digits versus Q3, although purchase accounting adjustments related to Harvest deconsolidation are expected to result in a net loss. Management highlighted Georgia growth and Texas expansion pending final approval, while noting Project Hyper AI benefits are expected to begin in Q1 2027.

Analysis

The key underwriting question is whether reported cash generation converts into durable, distributable cash after growth spending and tax uncertainty—not whether one strong quarter can be annualized. The medical-only reporting perimeter and Harvest deconsolidation complicate comparisons: treat the reported growth and margins as business-line signals, not clean evidence of consolidated acceleration. The anticipated Q4 GAAP loss may be noncash, but it can still obscure trend-following and index-driven demand; separate that accounting noise from operating cash flow.

Near term, holiday promotions could absorb some gross-margin gains. Over 1–3 months, watch for Georgia supply utilization and pharmacy onboarding: sevenfold unit growth from a newly expanded base is not yet proof of a scalable run rate. Over 6–18 months, Georgia capacity additions and Texas licensing could widen the growth runway, while also raising execution and capital-allocation risk. Texas remains an approval-dependent option, not current earnings power.

The potentially largest valuation catalyst is the asserted 280E relief, but the company also describes a substantial uncertain tax position, including prior refunds and accrued interest. Federal registration and management’s characterization of the business as federally legal should not be treated as equivalent to broad federal legalization or guaranteed tax resolution. Verify Treasury/IRS guidance, filings and cash-tax payments. No valuation or share-price data are supplied, so the call does not establish that the equity is cheap. The contrarian risk: investors may capitalize regulatory upside early while underweighting reinvestment needs, tax claims and the gap between management’s Texas timing and final licensure.

Key Decisions for Investors

• Do not chase the earnings headline without a valuation check. Keep Trulieve on a catalyst watchlist; reassess after the next filing confirms comparable medical-only results, cash conversion and actual cash taxes.
• Conditional position: initiate a modest long only after final Texas licensure or evidence that Georgia growth is translating into sustained sequential revenue and operating cash flow. Add only if growth is not being purchased through promotional margin giveback or outsized capex.
• Use the next quarter as the near-term test: monitor revenue against the low-single-digit sequential outlook, gross margin after holiday promotions, and operating cash flow. A miss alongside weaker margin would falsify the near-term operating-leverage thesis.
• Treat the 280E benefit as a contingent catalyst, not base-case upside, until tax guidance and the uncertain tax position are clarified. A material cash-tax liability, adverse IRS outcome, or delayed Texas approval would invalidate the regulatory-upside case.